최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.28 no.11 = no.223, 2018년, pp.1268 - 1276
최원경 (김천대학교 스포츠재활학과) , 최영현 (동의대학교 한의과대학 생화학교실)
The cytidine analog decitabine (DEC) acts as a nucleic acid synthesis inhibitor, whereas ammonium pyrrolidine dithiocarbamate (PDTC) is an inhibitor of nuclear factor-
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
세포사멸은 어떤 역할을 하는가? | 능동적 세포죽음의 대표적인 양식인 세포사멸(apoptosis)은 개체의 항상성 유지와 발생 과정에서 중요한 역할을 할 뿐만 아니라 다양한 질환의 발병과 진행에 핵심적인 역할을 한다[11, 15]. 따라서 표적 질환 예방과 치료를 위한 apoptosis 조절 경로의 파악은 필수적인 연구 분야이다. | |
decitabine는 어떤 기능을 하는 억제제 인가? | 그 중 decitabine (5-aza-2'-deoxycytidine, DEC)은 cytidine 유도체로서 핵산 합성의 대표적인 억제제이다[1, 6]. DEC는 암 억제 유전자의 활성을 방해하는 demethylation을 저해하여 암 억제유전자가 정상적인 기능을 갖게 하는 hypomethylating agent의 일종으로[1, 35], 특정 혈액 세포가 기능을 못하는 골수 이형성 증후군(myelodysplastic syndromes)의 치료를 위해 개발된 약물이다. 비록 DEC는 급성 골수성 백혈병(acute myeloid leukemia)의 치료제로 널리 사용되고 있으나, 혈구 수의 감소를 포함한 다양한 부작용을 유발한다[6, 30, 39]. | |
암세포의 증식 제어를 위한 수단으로 개발되는 약물은 크게 어떻게 대별되는가? | 암세포의 증식 제어를 위한 수단으로 개발되는 약물은 크게 핵산 생성의 저해와 세포 내 신호전달 교란 유도제로 대별될 수 있다. 그 중 decitabine (5-aza-2'-deoxycytidine, DEC)은 cytidine 유도체로서 핵산 합성의 대표적인 억제제이다[1, 6]. |
Appleton, K., Mackay, H. J., Judson, I., Plumb, J. A., McCormick, C., Strathdee, G., Lee, C., Barrett, S., Reade, S., Jadayel, D., Tang, A., Bellenger, K., Mackay, L., Setanoians, A., Schatzlein, A., Twelves, C., Kaye, S. B. and Brown, R. 2007. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25, 4603-4609.
Arlt, A., Gehrz, A., Muerkoster, S., Vorndamm, J., Kruse, M. L., Folsch, U. R. and Schafer, H. 2003. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22, 3243-3251.
Birch-Machin, M. A., Russell, E. V. and Latimer, J. A. 2013. Mitochondrial DNA damage as a biomarker for ultraviolet radiation exposure and oxidative stress. Br. J. Dermatol. 169, 9-14.
Chaudhary, A. K., Yadav, N., Bhat, T. A., O'Malley, J., Kumar, S. and Chandra, D. 2016. A potential role of X-linked inhibitor of apoptosis protein in mitochondrial membrane permeabilization and its implication in cancer therapy. Drug Discov. Today 21, 38-47.
Chen, D., Peng, F., Cui, Q. C., Daniel, K. G., Orlu, S., Liu, J. and Dou, Q. P. 2005. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front. Biosci. 10, 2932-2939.
Daskalakis, M., Blagitko-Dorfs, N. and Hackanson, B. 2010. Decitabine. Recent Results Cancer Res. 184, 131-157.
Decker, P. and Muller, S. 2002. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr. Pharm. Biotechnol. 3, 275-283.
Di Nicuolo, F., Serini, S., Boninsegna, A., Palozza, P. and Calviello, G. 2001. Redox regulation of cell proliferation by pyrrolidine dithiocarbamate in murine thymoma cells transplanted in vivo. Free Radic. Biol. Med. 31, 1424-1431.
Dorstyn, L., Akey, C. W. and Kumar, S. 2018. New insights into apoptosome structure and function. Cell Death Differ. 25, 1194-1208.
Farsinejad, S., Gheisary, Z., Ebrahimi Samani, S. and Alizadeh, A. M. 2015. Mitochondrial targeted peptides for cancer therapy. Tumour Biol. 36, 5715-5725.
Fulda, S. and Debatin, K. M. 2006. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811.
Gong, X. G., Lv, Y. F., Li, X. Q., Xu, F. G. and Ma, Q. Y. 2010. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells. Biol. Pharm. Bull. 33, 1261-1267.
Hajra, K. M. and Liu, J. R. 2004. Apoptosome dysfunction in human cancer. Apoptosis 9, 691-704.
Hata, A. N., Engelman, J. A. and Faber, A. C. 2015. The BCL2 family: Key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 5, 475-487.
Hengartner, M. O. 2000. The biochemistry of apoptosis. Nature 407, 770-776.
Hu, Q., Sun, W., Wang, C. and Gu, Z. 2016. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv. Drug Deliv. Rev. 98, 19-34.
Iessi, E., Logozzi, M., Mizzoni, D., Di Raimo, R., Supuran, C. T. and Fais, S. 2017. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites 8, E2.
Janssens, S. and Tschopp, J. 2006. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ. 13, 773-784.
Kantari, C. and Walczak, H. 2011. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim. Biophys. Acta. 1813, 558-563.
Katsman, A., Umezawa, K. and Bonavida, B. 2009. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr. Pharm. Des. 15, 792-808.
Kaufmann, T., Strasser, A. and Jost, P. J. 2012. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 19, 42-50.
Kroemer, G. and Pouyssegur, J. 2008. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482.
Malaguarnera, L., Pilastro, M. R., Vicari, L., Dimarco, R., Manzella, L., Palumbo, G. and Messina, A. 2005. Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity. Cancer Invest. 23, 404-412.
Mohamed, M. S., Bishr, M. K., Almutairi, F. M. and Ali, A. G. 2017. Inhibitors of apoptosis: Clinical implications in cancer. Apoptosis 22, 1487-1509.
Moloney, J. N. and Cotter, T. G. 2018. ROS signalling in the biology of cancer. Semin. Cell Dev. Biol. 80, 50-64.
Nakajima, K., Nangia-Makker, P., Hogan, V. and Raz, A. 2017. Cancer self-defense: An immune stealth. Cancer Res. 77, 5441-5444.
Nguyen, D. P., Li, J., Yadav, S. S. and Tewari, A. K. 2014. Recent insights into NF- ${\kappa}B$ signalling pathways and the link between inflammation and prostate cancer. BJU Int. 114, 168-176.
Nguyen, H. S., Shabani, S., Awad, A. J., Kaushal, M. and Doan, N. 2018. Molecular markers of therapy-resistant glioblastoma and potential strategy to combat resistance. Int. J. Mol. Sci. 19, E1765.
Pelicano, H., Carney, D. and Huang, P. 2004. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 7, 97-110.
Ranganathan, P., Yu, X., Santhanam, R., Hofstetter, J., Walker, A., Walsh, K., Bhatnagar, B., Klisovic, R., Vasu, S., Phelps, M. A., Devine, S., Shacham, S., Kauffman, M., Marcucci, G., Blum, W. and Garzon, R. 2015. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood 125, 2689-2692.
Reubold, T. F. and Eschenburg, S. 2012. A molecular view on signal transduction by the apoptosome. Cell Signal. 24, 1420-1425.
Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. and Bonner, W. M. 1998. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858-5868.
Rybak, P., Hoang, A., Bujnowicz, L., Bernas, T., Berniak, K., Zarebski, M., Darzynkiewicz, Z. and Dobrucki, J. 2016. Low level phosphorylation of histone H2AX on serine 139 ( ${\gamma}$ H2AX) is not associated with DNA double-strand breaks. Oncotarget 7, 49574-49587.
Shao, L., Wu, L. and Zhou, D. 2012. Sensitization of tumor cells to cancer therapy by molecularly targeted inhibition of the inhibitor of nuclear factor ${\kappa}B$ kinase. Transl. Cancer Res. 1, 100-108.
Stresemann, C. and Lyko, F. 2008. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123, 8-13.
Ta, M. H., Liuwantara, D. and Rangan, G. K. 2015. Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor- ${\kappa}B$ activity in autosomal dominant polycystic kidney disease cells. BMC Nephrol. 16, 212.
Tummers, B. and Green, D. R. 2017. Caspase-8: regulating life and death. Immunol. Rev. 277, 76-89.
Wadhwa, S. and Mumper, R. J. 2013. D-penicillamine and other low molecular weight thiols: review of anticancer effects and related mechanisms. Cancer Lett. 337, 8-21.
Wijermans, P. W., Ruter, B., Baer, M. R., Slack, J. L., Saba, H. I. and Lubbert, M. 2008. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk. Res. 32, 587-591.
Zhang, L., Li, J., Zong, L., Chen, X., Chen, K., Jiang, Z., Nan, L., Li, X., Li, W., Shan, T., Ma, Q. and Ma, Z. 2016. Reactive oxygen species and targeted therapy for pancreatic cancer. Oxid. Med. Cell. Longev. 2016, 1616781.
Zhang, X. Y. and Zhang, P. Y. 2016. Combinations in multimodality treatments and clinical outcomes during cancer. Oncol. Lett. 12, 4301-4304.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.